On Tuesday afternoon, the American College of Rheumatology (ACR) and the National Psoriasis Foundation (NPF) presented a draft of their new, jointly developed clinical guideline for treating psoriatic arthritis (PsA), at the ACR 2017 Annual Meeting.
On Tuesday afternoon at The American College of Rheumatology’s (ACR) 2017 Annual Meeting, ACR and the National Psoriasis Foundation (NPF) presented a draft of their new, jointly developed clinical guideline for treating psoriatic arthritis (PsA).
Development of the Guideline
Alexis Ogdie, MD, MSCE, addressed the method of developing the new approach to treating PsA, explaining that the ACR and NPF teams evaluated treatments including non-pharmacologic therapies (such as smoking cessation, weight loss, and exercise); symptomatic treatments (including non-steroidal anti-inflammatory drugs [NSAIDs], glucocorticoids, and local glucocorticoid injections); oral small molecule drugs (OSM, a term synonymous with, but preferred by the panel to, disease-modifying anti-rheumatic drugs [DMARDs]); tumor necrosis factor (TNF) inhibitors; IL-12 and IL-23 inhibitors; IL-17 inhibitors; abatacept; and tofacitinib.
Ogdie explained that ACR and NPF began by evaluating PICO questions (which consider the patient, intervention, comparison intervention, and outcome), investigating the level of evidence available to address each of the PICO questions, and making a recommendation that was either strong (based on good evidence) or conditional (based on a lower threshold of evidence). Strong recommendations are those that more than 50% of patients should adopt, and that could be adopted by policymakers in most situations.
A patient panel meeting in April 2017, which included 10 patients, addressed patient considerations in selecting a therapy, with patients listing treatment burden, onset of action, side effects, and effectiveness, among others, and key concerns.
Finally, a voting panel—comprising 2 patients, 11 rheumatologists, 1 rheumatology physician assistant, 1 dermatologist, and 1 dermatologist/rheumatologist—adopted recommendations that achieved a 70% or greater consensus.
Recommendations for Treatment
Jasvinder Singh, MD, MBBS, MPH, presented a sample of the 80 treatment recommendations established in the new guideline, noting that the 94% of the recommendations are conditional while 6% are strong. Among the example recommendations that Singh discussed are the following:
Treat-to-Target and Vaccination
The new guideline recommends a treat-to-target strategy, and recommends that patients initiate biologic treatment and then receive killed vaccines (rather than delaying treatment until after killed vaccines have been administered). It also recommends delaying the start of a biologic if the patient requires a live, attenuated vaccination.
Non-Pharmacological Treatments
The guideline gives a strong recommendation, with a high level of evidence, to smoking cessation in patients with PsA. Conditional recommendations include exercise (with low-impact exercise, such as Tai Chi, yoga, or swimming, noted as being preferable to high-impact exercise); physical therapy; occupational therapy; weight loss in the case of patients who are overweight or obese; massage therapy; and acupuncture.
Future Research and Added Guidelines
Singh pointed out that many common clinical situations in the treatment of PsA lack strong evidence in the medical literature. This lack of evidence suggests a need for greater investigation into the following areas:
Singh also pointed out room for improvement in the guideline, and specified the following as topics that the guideline could address in future revisions:
The group hopes to publish the guideline in a peer-reviewed journal and disseminate the document to the medical community shortly. ACR and NPF will continue to provide periodic literature search updates and annual reevaluations to the guideline.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More